Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

Analysts anticipate Twist Bioscience to report an earnings per share (EPS) of $-0.46. Anticipation surrounds Twist Bioscience ...

As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

Moderna Inc. continues to push its cost-savings work as Covid-19 vaccination rates decline. The company's third-quarter 2025 ...

In a market note, Mizuho Securities raised its rating for Sarepta Therapeutics Inc. (NASDAQ:SRPT) to “outperform” from ...

Ten stocks soared higher on Wednesday, mirroring a broader market rally, as investors continued to take path from a flurry of ...

Five-year follow-up data for Santhera Pharmaceuticals AG’s Duchenne muscular dystrophy (DMD) drug, Agamree (vamorolone), confirm that its efficacy in preserving muscle function is comparable to ...

Sarepta Therapeutics (SRPT) surged after Mizuho upgraded to Outperform, citing strong Elevidys uptake and gene therapy ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...

Fintel reports that on November 5, 2025, Mizuho upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Neutral ...

Shares in data analytics software developer Palantir tumble even as the company tops analysts’ earnings estimates.